|
SI2804617T1
(sl)
*
|
2012-01-17 |
2020-10-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Visokoafinitetni SIRP-alfa reagenti
|
|
KR102338833B1
(ko)
|
2012-02-06 |
2021-12-13 |
인히브릭스, 인크. |
Cd47 항체 및 그 사용 방법
|
|
ES2914814T3
(es)
*
|
2012-12-17 |
2022-06-16 |
Pf Argentum Ip Holdings Llc |
Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
|
|
PT2970493T
(pt)
*
|
2013-03-15 |
2019-06-27 |
Univ Leland Stanford Junior |
Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
|
|
ES2898627T3
(es)
|
2013-04-29 |
2022-03-08 |
Univ Leland Stanford Junior |
Uso de agentes anti-CD47 para mejorar la inmunización
|
|
ES2765483T3
(es)
*
|
2013-09-18 |
2020-06-09 |
Univ Leland Stanford Junior |
Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
|
|
EP3131917B1
(en)
|
2014-04-18 |
2020-06-17 |
The Board of Trustees of the Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to cd99
|
|
TWI759810B
(zh)
*
|
2014-08-08 |
2022-04-01 |
美商Ａｌｘ腫瘤技術股份有限公司 |
信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
|
|
US10087257B2
(en)
|
2014-08-08 |
2018-10-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP alpha-antibody fusion proteins
|
|
WO2016023001A1
(en)
*
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multispecific high affinity pd-1 agents and methods of use
|
|
US9546206B2
(en)
|
2014-08-08 |
2017-01-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
|
HUE046661T2
(hu)
|
2014-08-15 |
2020-03-30 |
Merck Patent Gmbh |
SIRP-alfa immunglobulin fúziós proteinek
|
|
FI3656869T4
(fi)
|
2014-08-26 |
2025-06-04 |
Univ Leland Stanford Junior |
Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
|
|
EP3194024B1
(en)
*
|
2014-09-15 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
|
EP3209769B1
(en)
|
2014-10-24 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
|
EP3012271A1
(en)
|
2014-10-24 |
2016-04-27 |
Effimune |
Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
|
|
CA2967379A1
(en)
*
|
2014-11-18 |
2016-05-26 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
|
WO2016109415A1
(en)
*
|
2014-12-30 |
2016-07-07 |
Celgene Corporation |
Anti-cd47 antibodies and uses thereof
|
|
US11253588B2
(en)
|
2015-02-27 |
2022-02-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Combination therapy for treatment of coronary artery disease
|
|
CN106146670B
(zh)
*
|
2015-04-24 |
2019-01-15 |
宜明昂科生物医药技术（上海）有限公司 |
一种新的重组双功能融合蛋白及其制备和应用
|
|
US10358472B2
(en)
|
2015-05-06 |
2019-07-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity CD47 analogs
|
|
CA2994935A1
(en)
|
2015-05-18 |
2016-11-24 |
Ab Initio Biotherapeutics, Inc. |
Sirp polypeptide compositions and methods of use
|
|
BR102016018074A2
(pt)
|
2015-08-07 |
2021-11-16 |
ALX Oncology Inc. |
Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
|
|
WO2017027422A1
(en)
|
2015-08-07 |
2017-02-16 |
Alexo Therapeutics Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
EP3341015B2
(en)
|
2015-08-26 |
2023-12-27 |
The Board of Trustees of the Leland Stanford Junior University |
Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
|
|
AU2016365829B2
(en)
|
2015-12-11 |
2020-02-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of cancer with dual targeting of CD47 and EGFR
|
|
EP3747906A1
(en)
|
2016-01-11 |
2020-12-09 |
Forty Seven, Inc. |
Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
|
|
RS66062B1
(sr)
|
2016-04-14 |
2024-11-29 |
Ose Immunotherapeutics |
Nova anti-sirpa antitela i njihove terapijske primene
|
|
AU2017250809B2
(en)
|
2016-04-15 |
2024-02-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
|
|
US11649284B2
(en)
|
2016-04-18 |
2023-05-16 |
Baylor College Of Medicine |
Cancer gene therapy targeting CD47
|
|
WO2017190148A1
(en)
|
2016-04-29 |
2017-11-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for the prevention and treatment of surgical adhesions
|
|
US11560433B2
(en)
|
2016-05-27 |
2023-01-24 |
Albert Einstein College Of Medicine |
Methods of treatment by targeting VCAM1 and MAEA
|
|
US10148939B2
(en)
|
2016-07-19 |
2018-12-04 |
Gopro, Inc. |
Mapping of spherical image data into rectangular faces for transport and decoding across networks
|
|
EP3532497B1
(en)
*
|
2016-10-26 |
2024-07-24 |
The Board of Trustees of the Leland Stanford Junior University |
Modified immunoglobulin hinge regions to reduce hemagglutination
|
|
CA3042581A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
WO2018081898A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Improvements in cd47 blockade therapy by hdac inhibitors
|
|
EP3563835A4
(en)
*
|
2016-12-29 |
2020-12-30 |
Korea Institute of Science and Technology |
NEW EXOSOME-BASED ANTI-CANCER AGENT
|
|
US11566060B2
(en)
|
2017-01-05 |
2023-01-31 |
Kahr Medical Ltd. |
PD1-CD70 fusion protein and methods of use thereof
|
|
LT3565579T
(lt)
|
2017-01-05 |
2023-09-11 |
Kahr Medical Ltd. |
Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
|
|
PT3565828T
(pt)
|
2017-01-05 |
2022-02-08 |
Kahr Medical Ltd |
Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
|
|
JP2020505016A
(ja)
|
2017-01-06 |
2020-02-20 |
シンロジック オペレーティング カンパニー インコーポレイテッド |
腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物
|
|
JP7321934B2
(ja)
|
2017-01-30 |
2023-08-07 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
幹細胞移植のための非遺伝毒性移植前処置レジメン
|
|
EP3589368A4
(en)
|
2017-02-28 |
2021-03-24 |
The Board of Trustees of the Leland Stanford Junior University |
ANTIFIBROTIC ACTIVITY OF CD47 BLOCKING
|
|
US11078272B2
(en)
|
2017-03-09 |
2021-08-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of pediatric brain tumors with targeting of CD47 pathway
|
|
SI3642242T1
(sl)
|
2017-06-21 |
2024-05-31 |
The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel |
Parametri odmerjanja za terapije, ki ciljajo na CD47, za hematološke malignosti
|
|
CN111246865A
(zh)
|
2017-07-12 |
2020-06-05 |
同生运营公司 |
程序化以在肿瘤细胞中产生免疫调节剂和抗癌治疗剂的微生物
|
|
JP7262440B2
(ja)
|
2017-08-02 |
2023-04-21 |
フェインズ セラピューティクス，インコーポレーテッド |
抗ｃｄ４７抗体及びその使用
|
|
CN111051350B
(zh)
*
|
2017-09-07 |
2022-11-01 |
苏州丁孚靶点生物技术有限公司 |
包含信号调节蛋白α的免疫缀合物
|
|
WO2019061012A1
(zh)
*
|
2017-09-26 |
2019-04-04 |
南京凯地生物科技有限公司 |
靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用
|
|
JP7395471B2
(ja)
|
2017-10-13 |
2023-12-11 |
オーセ イミュノセラピューティクス |
改変抗ＳＩＲＰａ抗体及びその使用
|
|
SI4177270T1
(sl)
|
2017-10-18 |
2024-10-30 |
Forty Seven, Inc. |
Terapija za raka jajčnikov na osnovi sredstva proti cd47
|
|
US11771764B2
(en)
|
2017-11-06 |
2023-10-03 |
Pfizer Inc. |
CD47 blockade with radiation therapy
|
|
KR20200091901A
(ko)
*
|
2017-12-01 |
2020-07-31 |
시애틀 지네틱스, 인크. |
암을 치료하기 위한 cd47 항체 및 이의 용도
|
|
WO2019109357A1
(zh)
*
|
2017-12-08 |
2019-06-13 |
杭州翰思生物医药有限公司 |
抗pd-1/cd47的双特异性抗体及其应用
|
|
CN109971716B
(zh)
*
|
2017-12-28 |
2023-08-01 |
上海细胞治疗研究院 |
自分泌cd47抗体的egfr特异性car-t细胞及其用途
|
|
AU2019218271B2
(en)
|
2018-02-12 |
2024-12-12 |
Forty Seven, LLC |
Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
|
|
CN108484774B
(zh)
*
|
2018-03-09 |
2021-11-05 |
上海高菲生物科技有限公司 |
一种SIRPα融合蛋白及其制备方法和用途
|
|
US20210040219A1
(en)
*
|
2018-03-13 |
2021-02-11 |
Trillium Therapeutics Inc. |
Improvements in cd47 blockade therapy by egfr antibody
|
|
AU2019233577A1
(en)
|
2018-03-13 |
2020-09-03 |
Ose Immunotherapeutics |
Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
|
|
CN108872569A
(zh)
*
|
2018-06-19 |
2018-11-23 |
浠思（上海）生物技术有限公司 |
利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法
|
|
KR20250079073A
(ko)
|
2018-07-10 |
2025-06-04 |
고쿠리츠다이가쿠호진 고베다이가쿠 |
항 SIRPα 항체
|
|
US12134638B2
(en)
|
2018-07-11 |
2024-11-05 |
Kahr Medical Ltd. |
SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
|
|
KR20210044221A
(ko)
|
2018-07-11 |
2021-04-22 |
카 메디컬 리미티드 |
Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법
|
|
KR102129522B1
(ko)
*
|
2018-07-26 |
2020-07-02 |
한국과학기술연구원 |
암세포 특이적 항암 단백질-형광 복합체 및 이를 포함하는 암의 진단 및 영상화용 조성물
|
|
WO2020047326A2
(en)
|
2018-08-31 |
2020-03-05 |
ALX Oncology Inc. |
Decoy polypeptides
|
|
JP7557920B2
(ja)
|
2018-09-04 |
2024-09-30 |
ファイザー・インク |
疾患治療のためのｐａｒｐ阻害と組み合わせたｃｄ４７遮断
|
|
CN109306017B
(zh)
*
|
2018-10-12 |
2021-02-09 |
倍而达药业（苏州）有限公司 |
一种基于SIRP-αD1突变体制备的重组蛋白及应用
|
|
EP3878469A4
(en)
*
|
2018-11-07 |
2022-08-03 |
Daiichi Sankyo Company, Limited |
METHOD OF IMPROVING THE BLOOD KINETICS OF A PEPTID
|
|
CN111303293B
(zh)
|
2018-11-14 |
2022-08-30 |
杭州尚健生物技术有限公司 |
一种融合蛋白及其用途
|
|
US20220023348A1
(en)
|
2018-11-28 |
2022-01-27 |
Forty Seven, Inc. |
Genetically modified hspcs resistant to ablation regime
|
|
US20220289821A1
(en)
*
|
2018-11-29 |
2022-09-15 |
Trillium Therapeutics Inc |
Biomarkers for cd47 blockade therapy
|
|
AU2019409805A1
(en)
|
2018-12-21 |
2021-07-22 |
Ose Immunotherapeutics |
Bifunctional anti-PD-1/SIRPA molecule
|
|
AU2020243431B2
(en)
|
2019-03-18 |
2025-12-18 |
Ludwig Institute For Cancer Research Ltd. |
A2/NY-ESO-1 specific T cell receptors and uses thereof
|
|
BR112021024003A2
(pt)
|
2019-05-31 |
2022-04-19 |
Alx Oncology Inc |
Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
|
|
CN114206912B
(zh)
|
2019-06-07 |
2025-02-11 |
Alx肿瘤生物技术公司 |
用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
|
|
WO2020257196A1
(en)
*
|
2019-06-17 |
2020-12-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating infections by blocking pathogen mimics of cd47
|
|
CN114761041A
(zh)
|
2019-07-16 |
2022-07-15 |
吉利德科学公司 |
Hiv疫苗及其制备和使用方法
|
|
CN114555123B
(zh)
|
2019-10-18 |
2024-04-02 |
四十七公司 |
用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
|
|
KR20220091576A
(ko)
|
2019-10-31 |
2022-06-30 |
포티 세븐, 인코포레이티드 |
혈액암의 항-cd47 및 항-cd20 기반 치료
|
|
AU2020394204A1
(en)
|
2019-11-27 |
2022-06-02 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
LT4081305T
(lt)
|
2019-12-24 |
2024-11-25 |
Carna Biosciences, Inc. |
Diacilglicerolio kinazę moduliuojantys junginiai
|
|
KR20260017503A
(ko)
|
2020-02-14 |
2026-02-05 |
길리애드 사이언시즈, 인코포레이티드 |
Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
US20230220342A1
(en)
*
|
2020-04-24 |
2023-07-13 |
Georgia State University Research Foundation, Inc. |
SIRPa Deficient Macrophages for Treating Cancer
|
|
US12343377B2
(en)
|
2020-06-01 |
2025-07-01 |
ALX Oncology Inc. |
Combination therapies comprising a hypomethylation agent for treating cancer
|
|
CN116133679A
(zh)
|
2020-06-30 |
2023-05-16 |
门德斯有限公司 |
白血病衍生细胞在卵巢癌疫苗中的用途
|
|
WO2022010806A1
(en)
|
2020-07-06 |
2022-01-13 |
ALX Oncology Inc. |
Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
|
|
CN114057888A
(zh)
*
|
2020-07-30 |
2022-02-18 |
三生国健药业（上海）股份有限公司 |
一种SIRPα-Fc融合蛋白
|
|
JP7446953B2
(ja)
*
|
2020-08-27 |
2024-03-11 |
株式会社三共 |
遊技機
|
|
KR102557016B1
(ko)
*
|
2020-09-22 |
2023-07-20 |
비피진 주식회사 |
암 치료를 위한 cd47 바인더 및 리포좀 복합체
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
AU2021370483A1
(en)
*
|
2020-10-28 |
2023-06-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Cd47 blockade and combination therapies thereof for reduction of vascular inflammation
|
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
WO2022229818A1
(en)
|
2021-04-27 |
2022-11-03 |
Pf Argentum Ip Holdings Llc |
Enhancement of cd47 blockade therapy with dhfr inhibitors
|
|
JP2024520902A
(ja)
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
KR20230016152A
(ko)
*
|
2021-07-19 |
2023-02-01 |
주식회사유한양행 |
Sirp-alpha 변이체 및 이의 용도
|
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
WO2023073580A1
(en)
|
2021-10-29 |
2023-05-04 |
Pfizer Inc. |
Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy
|
|
EP4422756A1
(en)
|
2021-10-29 |
2024-09-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
WO2023072279A1
(zh)
*
|
2021-11-01 |
2023-05-04 |
江苏先声药业有限公司 |
SIRPa突变体及其应用
|
|
US20250367255A1
(en)
|
2021-11-08 |
2025-12-04 |
Pfizer Inc. |
Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
WO2023121887A2
(en)
*
|
2021-12-21 |
2023-06-29 |
Fbd Biologics Limited |
ENGINEERED SIRPα VARIANTS AND METHODS OF USE THEREOF
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
EP4452415B1
(en)
|
2021-12-22 |
2026-02-25 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
US20250051441A1
(en)
*
|
2021-12-23 |
2025-02-13 |
Fbd Biologics Limited |
Cd47/4-1bb-targeting protein complex and methods of use thereof
|
|
CN118401564A
(zh)
*
|
2022-01-18 |
2024-07-26 |
Fbd生物制品有限公司 |
靶向cd47/pd-l1的蛋白质复合物和其使用方法
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
CA3253296A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
IL315706A
(en)
|
2022-03-24 |
2024-11-01 |
Bitterroot Bio Inc |
Sirp-alpha fusion polypeptides with modified fc domains
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
WO2023183890A1
(en)
|
2022-03-24 |
2023-09-28 |
Bitterroot Bio, Inc. |
Multivalent sirp-alpha fusion polypeptides
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2023263628A1
(en)
*
|
2022-05-06 |
2024-12-19 |
Biosion Inc. |
Recombinant fusion protein targeting cd40 and cd47
|
|
JP2025518578A
(ja)
|
2022-05-25 |
2025-06-17 |
ファイザー・インク |
がんの処置のためのｓｉｒｐアルファ融合タンパク質の投薬レジメン
|
|
JP2025523369A
(ja)
|
2022-06-01 |
2025-07-23 |
エーエルエックス オンコロジー インコーポレイテッド |
尿路上皮癌腫を治療するための併用療法
|
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CN119677546A
(zh)
|
2022-07-12 |
2025-03-21 |
吉利德科学公司 |
Hiv免疫原性多肽和疫苗及其用途
|
|
US20260103501A1
(en)
*
|
2022-07-15 |
2026-04-16 |
Nutcracker Therapeutics, Inc. |
MRNA Therapies Including SIRP-ALPHA
|
|
WO2024040151A1
(en)
|
2022-08-18 |
2024-02-22 |
Pfizer Inc. |
Sirp alpha fusion protein and anti-cd38 antibody combination therapies
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
CN120390653A
(zh)
|
2022-12-09 |
2025-07-29 |
辉瑞大药厂 |
Cd47阻断剂及抗bcma/抗cd3双特异性抗体的组合疗法
|
|
WO2024124107A2
(en)
|
2022-12-09 |
2024-06-13 |
Pfizer Inc. |
Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024193635A1
(en)
*
|
2023-03-22 |
2024-09-26 |
Wangzhi LI |
Sirp variants and uses thereof
|
|
CN120882725A
(zh)
|
2023-04-11 |
2025-10-31 |
吉利德科学公司 |
Kras调节化合物
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024245380A1
(en)
*
|
2023-05-31 |
2024-12-05 |
Fbd Biologics Limited |
Cd47/pd-l1-targeting protein complex and methods of use thereof
|
|
KR20260019369A
(ko)
|
2023-05-31 |
2026-02-10 |
에프비디 바이올로직스 리미티드 |
Cd47/pd-l1-표적화 단백질 복합체 및 그의 사용 방법
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025247303A1
(zh)
*
|
2024-05-30 |
2025-12-04 |
上海艾乐晞生物科技有限公司 |
具有pH依赖结合活性的人信号调节蛋白α突变体及其应用
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2026062544A1
(en)
|
2024-09-23 |
2026-03-26 |
Pfizer Inc. |
Sirp alpha fusion protein formulation
|